Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by the Centre for Reviews and Dissemination (CRD), Centre for Health Economics (CHE), The University of York:

  • Paton F et al. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix, April 2009

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I and II also have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • GlaxoSmithKline (topotecan)

II) Professional/specialist and patient/carer groups:

  • Cancer Research UK

  • Jo's Trust

  • Rarer Cancers Forum

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

  • Royal College of Radiologists

  • United Kingdom Oncology Nursing Society

III) Other consultees

  • Department of Health

  • Welsh Assembly Government

IV) Commentator organisations (did not provide written evidence and without the right of appeal)

  • Centre for Reviews and Dissemination, Centre for Health Economics, The University of York

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • National Collaborating Centre for Cancer

  • National Institute for Health Research Health Technology Assessment Programme

  • NHS Quality Improvement Scotland

  • Pfizer

C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Lynn Hirschowitz – Consultant Gynaecological Pathologist, nominated by The Royal College of Pathologists – clinical specialist

  • Dr Paul Symonds – Reader in Oncology/Consultant Oncologist, nominated by The Royal College of Physicians – clinical specialist

  • Ms Catherine Oakley – Chemotherapy Nurse Consultant, nominated by United Kingdom Oncology Nursing Society – clinical specialist

  • Ms Stella Pendleton – Executive Director, nominated by Rarer Cancers Forum – patient expert

  • National Institute for Health and Care Excellence (NICE)